Immunome Inc 10-Q for FY2026 Q3
Immunome Inc. (IMNM)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
Immunome Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Immunome Inc. reported positive Phase 3 RINGSIDE results for varegacestat and said the FDA accepted its NDA, assigning a PDUFA target action date of April 28, 2027. The company has generated no product-sales revenue. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $0
- compared with $0 a year earlier
- Net loss
- $85.78M
- compared with a net loss of $57.46M a year earlier
- Diluted EPS
- -$0.76
- compared with -$0.65 a year earlier